Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines

Devarbhavi H 1 , Aithal G 2 , Treeprasertsuk S 3 , Takikawa H 4 , Mao Y 5 , Shasthry SM 6 Show all authors , Hamid S 7 , Tan SS 8 , Philips CA 9 , George J 10 , Jafri W 7 , Sarin SK 11 , Asia Pacific Association of Study of Liver

Affiliations 

  • 1 Department of Gastroenterology and Hepatology, St John's Medical College Hospital, Bangalore, India. harshad.devarbhavi@gmail.com
  • 2 NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK
  • 3 Department of Medicine, Chulalongkorn University, Bangkok, Thailand
  • 4 Faculty of Medical Technology, Emeritus Professor, School of Medicine, Tokyo, Japan
  • 5 Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, and Clinical Research Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • 6 Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India
  • 7 Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan
  • 8 Department of Medicine, Hospital Selayang, Bata Caves, Selangor, Malaysia
  • 9 The Liver Institute, Center of Excellence in GI Sciences, Rajagiri Hospital, Aluva, Kerala, India
  • 10 Department of Gastroenterology and Hepatology, Westmead Hospital and Sydney West Local Health District, Sydney, Australia
  • 11 Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India. shivsarin@gmail.com
Hepatol Int, 2021 Apr;15(2):258-282.
PMID: 33641080 DOI: 10.1007/s12072-021-10144-3

Abstract

Idiosyncratic drug-induced liver injury mimics acute and chronic liver disease. It is under recognized and underrecognised because of the lack of pathognomonic diagnostic serological markers. Its consequences may vary from being asymptomatic to self-limiting illness to severe liver injury leading to acute liver failure. Its incidence is likely to be more common in Asia than other parts of the world, mainly because of hepatotoxicity resulting from the treatment of tuberculosis disease and the ubiquitous use of traditional and complimentary medicines in Asian countries. This APASL consensus guidelines on DILI is a concise account of the various aspects including current evidence-based information on DILI with special emphasis on DILI due to antituberculosis agents and traditional and complementary medicine use in Asia.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications